In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Swati ChandlaKarsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048 USA.ORCID 0000-0002-6880-8095 Youngyi LimKarsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048 USA.ORCID 0000-0002-5609-8356 Andrea FlorisKarsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048 USA.
Michael MazareiKarsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048 USA.ORCID 0000-0002-8592-6464 Xi YangKarsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048 USA.
Takashi TsuchiyaKarsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048 USA.ORCID 0000-0002-3134-0986 Manisha DagarKarsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048 USA.
Alfonso DarmawanKarsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048 USA.ORCID 0009-0005-6418-6531 Monica JustoDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048 USA.
Ramachandran MuraliDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048 USA.ORCID 0000-0002-8384-2793 Alexandra GangiDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048 USA.
Ivan TomasiDepartment of General Surgery, Guys and St Thomas Hospital, London SE1 7EH, UK.
Nirmala MavilaKarsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048 USA.ORCID 0000-0002-5608-3349 Komal RamaniKarsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048 USA.ORCID 0000-0002-2387-4603 Maria Lauda TomasiKarsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048 USA.ORCID 0000-0001-8156-9052 Funding
Role of phospho UBC9 in alcohol-associated liver diseaseR01AA029723 · NIAAA · CEDARS-SINAI MEDICAL CENTER · PI Maria Lauda Tomasi · 2022 to 2026
$2.2MA-Kinase Anchoring Protein Dysregulation during Alcohol-Associated Liver DiseaseR01AA029988 · NIAAA · CEDARS-SINAI MEDICAL CENTER · PI Komal Ramani · 2022 to 2026
$1.7MNIAAA NIH HHS R01 AA029723NIAAA NIH HHS R01 AA029988
6 · The paper itselfAbstract
Alcohol-associated liver disease (ALD) remains a major public health challenge with limited treatment options. NF-κB-driven inflammation in Kupffer cells (KCs) plays a central role in ALD, but the upstream regulators remain poorly understood. Here, we identify the tyrosine kinase SRC as a key mediator of ALD. Chronic ethanol exposure activates SRC in KCs, which directly phosphorylates ubiquitin-conjugating enzyme 9 (UBC9), the only E2 SUMO enzyme, at tyrosine-68 (Y68). This modification enhances NF-κB signaling and increases proinflammatory cytokines (TNF-α, IL-6, and IL-1β). These cytokines then promote hepatic lipogenesis through SREBP1c- and CEBPβ-dependent induction of FASN and ACC. Inhibition of UBC9 phosphorylation by gene editing or SRC inhibitor reduces NF-κB-dependent inflammation and lessens ethanol-induced liver injury in mouse models. These findings uncover a previously unrecognized SRC-UBC9-NF-κB axis that drives inflammation in ALD and highlight it as a potential therapeutic target in liver disease.
Indexed as
Liver Diseases, AlcoholicSignal Transductionsrc-Family KinasesUbiquitin-Conjugating EnzymesAnimalsCytokinesDisease Models, AnimalEthanolHumansInflammationKupffer CellsMaleMiceNF-kappa BPhosphorylationUbiquitin-Conjugating Enzyme UBC9CytokinesEthanolNF-kappa Bsrc-Family KinasesUbiquitin-Conjugating EnzymesUbiquitin-Conjugating Enzyme UBC9
Identifiers
PMID41961938
PMCPMC13068051
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390